Protara Therapeutics (TARA) Competitors $3.29 -0.08 (-2.37%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$3.36 +0.07 (+2.25%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARA vs. AUTL, ETON, ATAI, SANA, ZVRA, AMLX, PRTC, SEPN, ORKA, and TRMLShould you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Autolus Therapeutics (AUTL), Eton Pharmaceuticals (ETON), Atai Life Sciences (ATAI), Sana Biotechnology (SANA), Zevra Therapeutics (ZVRA), Amylyx Pharmaceuticals (AMLX), PureTech Health (PRTC), Septerna (SEPN), Oruka Therapeutics (ORKA), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry. Protara Therapeutics vs. Its Competitors Autolus Therapeutics Eton Pharmaceuticals Atai Life Sciences Sana Biotechnology Zevra Therapeutics Amylyx Pharmaceuticals PureTech Health Septerna Oruka Therapeutics Tourmaline Bio Protara Therapeutics (NASDAQ:TARA) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation. Do analysts rate TARA or AUTL? Protara Therapeutics currently has a consensus price target of $20.50, indicating a potential upside of 523.10%. Autolus Therapeutics has a consensus price target of $9.32, indicating a potential upside of 316.07%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Protara Therapeutics is more favorable than Autolus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, TARA or AUTL? Protara Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtara TherapeuticsN/AN/A-$40.42M-$1.72-1.91Autolus Therapeutics$9.01M66.16-$208.38M-$0.88-2.55 Does the MarketBeat Community prefer TARA or AUTL? Autolus Therapeutics received 188 more outperform votes than Protara Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Protara Therapeutics an outperform vote while only 68.25% of users gave Autolus Therapeutics an outperform vote. CompanyUnderperformOutperformProtara TherapeuticsOutperform Votes4270.00% Underperform Votes1830.00% Autolus TherapeuticsOutperform Votes23068.25% Underperform Votes10731.75% Which has more volatility & risk, TARA or AUTL? Protara Therapeutics has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Do insiders and institutionals have more ownership in TARA or AUTL? 38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are owned by institutional investors. 8.4% of Protara Therapeutics shares are owned by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor TARA or AUTL? In the previous week, Protara Therapeutics had 2 more articles in the media than Autolus Therapeutics. MarketBeat recorded 7 mentions for Protara Therapeutics and 5 mentions for Autolus Therapeutics. Protara Therapeutics' average media sentiment score of 1.17 beat Autolus Therapeutics' score of 0.93 indicating that Protara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protara Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Autolus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TARA or AUTL more profitable? Protara Therapeutics' return on equity of -55.96% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protara TherapeuticsN/A -55.96% -49.06% Autolus Therapeutics N/A -63.65%-36.54% SummaryProtara Therapeutics beats Autolus Therapeutics on 10 of the 17 factors compared between the two stocks. Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARA vs. The Competition Export to ExcelMetricProtara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$126.94M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio-1.1733.3227.1420.06Price / SalesN/A469.84411.98157.10Price / CashN/A168.6838.2534.64Price / Book0.553.457.064.70Net Income-$40.42M-$72.35M$3.23B$247.88M7 Day Performance5.45%6.23%2.85%2.63%1 Month Performance0.61%16.53%9.06%6.36%1 Year Performance24.15%-16.90%31.43%14.05% Protara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARAProtara Therapeutics2.4871 of 5 stars$3.29-2.4%$20.50+523.1%+20.1%$126.94MN/A-1.1730Analyst RevisionGap UpAUTLAutolus Therapeutics2.6465 of 5 stars$1.91+9.1%$9.32+388.0%-48.0%$508.33M$9.01M-1.58330Positive NewsETONEton Pharmaceuticals2.5183 of 5 stars$18.84-0.3%$29.67+57.5%+316.9%$505.25M$48.33M-85.6420Short Interest ↑Analyst RevisionATAIAtai Life Sciences3.3091 of 5 stars$2.49+7.8%$8.67+248.1%+68.9%$498.84M$1.86M-3.0780Analyst RevisionGap UpHigh Trading VolumeSANASana Biotechnology2.4752 of 5 stars$2.20+1.4%$10.80+390.9%-60.8%$496.05MN/A-1.57380Positive NewsZVRAZevra Therapeutics2.9058 of 5 stars$8.66+1.3%$22.29+157.3%+93.8%$473.53M$40.59M-4.4020Positive NewsAnalyst RevisionAMLXAmylyx Pharmaceuticals4.1698 of 5 stars$5.10-1.0%$9.83+92.8%+211.5%$454.62M-$1.27M-1.34200PRTCPureTech Health2.2486 of 5 stars$18.47+0.2%$45.00+143.7%-35.4%$443.51M$4.32M0.00100Positive NewsSEPNSepterna2.217 of 5 stars$9.93+7.4%$27.00+171.9%N/A$442.46M$977K0.00N/APositive NewsAnalyst RevisionORKAOruka Therapeutics3.086 of 5 stars$11.77+7.4%$40.38+243.0%N/A$440.68MN/A-1.88N/APositive NewsTRMLTourmaline Bio2.8328 of 5 stars$17.11+2.6%$49.33+188.3%+22.2%$439.47MN/A-6.0744Positive NewsAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies AUTL Alternatives ETON Alternatives ATAI Alternatives SANA Alternatives ZVRA Alternatives AMLX Alternatives PRTC Alternatives SEPN Alternatives ORKA Alternatives TRML Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TARA Stock Free TARA Stock Alerts